Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

TTP Labtech Announces On-Going Growth

Published: Thursday, July 11, 2013
Last Updated: Thursday, July 11, 2013
Bookmark and Share
An investment of £3.8M in global R&D sees product sales grow over 20%.

TTP Labtech has reported details of its success in 2012, as well as its growth plans for 2013. Continuing its track record of pioneering automation drug discovery products, TTP Labtech’s £3.8M investment in R&D and entrance into new markets paid off as product sales for 2012 were up over 20 percent compared to the year previous, despite the challenging economy. This progress was driven by launching products into new markets, including biological sample storage and liquid handling for molecular biology applications, as well as continued growth in the sale of established products. 

“Many drug discovery laboratories are facing challenging circumstances that require them to continually optimise their screening strategies and harness more automation,” said Jas Sanghera, TTP Labtech’s Managing Director. “We’re poised to embrace these changes in the environment by driving the development of solutions that meet the ever-evolving needs of our customers and applying this insight to new market sectors.” 

As such, the company shifted emphasis slightly during 2012 to make more effective use of its considerable product development expertise, positioning it for strong growth this year. “When we started over a decade ago, we primarily provided consultative insight for customers requiring bespoke automated platforms,” commented Sanghera. “However, over the last few years, our internal R&D teams have proved time and time again to be exceptionally good at developing innovative new automated technologies that truly meet customer needs. In 2012, we continued to invest in our product development capabilities and see product sales as being a strong driver of revenue growth into 2013 and beyond.”

This approach has included optimising every department within the company to reflect the growing focus on the continual development of automated instrumentation for the life science industry. Importantly, TTP Labtech uses its consultative experience to help customers develop new applications and techniques, with customer needs forming a key driving force behind its R&D programs. 

“We trust the team at TTP Labtech implicitly, they always listen to us.” said Jose Quiroz of Dart NeuroScience LLC. “We have developed such good working relationships with them that we consider them friends – their engineering and support teams regularly visit us to follow-up on our progress. Their applications support has always been second to none.”  

Last year, the company introduced an automated -80°C biological sample management system for biobanking called arktic® and the dragonfly, a new liquid handler specifically developed for screen optimisation. Both have been enthusiastically welcomed by the market and are expected to perform well in 2013. The mirrorball® antibody discovery system, which was introduced in late 2011 and is the world’s first simultaneous multi-laser scanning system, is also rapidly gaining traction in the pharmaceutical and biotech sectors, and will start to significantly impact revenues during 2013. Furthermore, the new high content imager, acumen hci, is extremely well positioned to handle the high throughput imaging and analysis of complex cellular assays, which is now common place in the high content screening market. 

This year, the company will look to target the field of molecular biology. “Many of our products are well positioned to provide real value to customers carrying out analysis applications such as next generation sequencing (NGS) and qPCR by improving the efficiency and speed of sample preparation, as well as improving functional genomics studies, for example via automated RNAi screens,” said Sanghera. “With significant opportunities in this space and several other major product developments coming in 2013, these are exciting times for TTP Labtech.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TTP Labtech will Showcase its Latest Automated Technology Innovations in Europe
Delivering a wealth of new products to the attendees of ELA 2012.
Monday, May 21, 2012
TTP LabTech's European Roadshow
The roadshow offers the opportunity to try out the latest in low-volume liquid handling and high content screening systems, as well as learning more about compound management, instrumentation development and custom automation.
Thursday, September 13, 2007
TTP LabTech Announce US Expansion to Meet Growing Customer Demand
TTP LabTech further expands its US facilities with the recruitment of sales and customer service personnel for its East Coast office in Cambridge, MA.
Monday, July 30, 2007
TTP Extends Global Reach
After building up a strong base of customers in the USA and Europe over the past three years, TTP LabTech have now appointed distributors for Japan, India and Australia/New Zealand.
Wednesday, April 04, 2007
Scientific News
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Potential Target for Revolutionary Antibiotics
An international team of including the Lomonosov Moscow State University researchers discovered which enzyme enables Escherichia coli bacterium (E. coli) to breathe.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
Activating Cancer-Killing Immune Cells
A UCL research team have discovered that cutting off a sleep-switch on immune cells inside a tumour wakes up the cells and enables the immune system to hunt down and destroy cancer.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!